Search Immortality Topics:

Page 11,411«..1020..11,41011,41111,41211,413..11,42011,430..»


South Korean lawmakers one step from rigorous new system for stem cell Advancement: scientists, physicians and …

Posted: September 20, 2012 at 6:10 am

SEOUL, South Korea, Sept. 19, 2012 /PRNewswire/ -- Seung-Jo Yang, a Parliament member, prepared a bill proposing new law for the management and transplantation of stem cells. On September 17, the National Health and Welfare Committee referred the bill to the Conference for review. The previous 18th National Assembly proposed a similar stem cell bill when much of its term had already passed so it was not fully discussed until the period ended, disappointing many patients with rare diseases. The Bill was referred to the 19th National Assembly, though, which shows the willingness of South Korean leaders to meet the expectations that this new law will be passed coming from the medical community and patient groups throughout South Korea.

Dr. Jeong-Chan Ra, president of RNL BIO's stem cell technology institute said "This effort for new stem cell bill will advance the use and sophistication of autologous adult stem cell technology as a powerful solution for overcoming incurable diseases." Dr. Ra, whose pioneering efforts in Korean stem cell research are known worldwide, is equally known in Korea as an ardent advocate for governmental investment in regenerative medicine. Perhaps no scientist has pushed harder for rigorous standards for stem cell banking, which this proposal may at last bring to fruition.

In South Korea stem cell banks have not been operated under a specific legal structure, so development and progress has been limited. The proposed law suggests that the harvesting and preservation of stem cells must be controlled by national regulation, specifically a management system for stem cell harvesting, storage and implantation. Through this, stem cell experts expect growth in responsible stem cell research and faster, even safer development of therapeutics.

Additionally, the current Korean policy requires stem cell programs - regardless of whether there are available therapies for patients with any particular condition - to complete clinical trial phase III for market approval. Had such rules been in place, for example, for the treatment of H.I.V., tens of thousands of people would have died. Many treatments for those with incurable diseases have been approved without completion of Phase III including stem cell treatments in other nations, even for the treatment of HIV, which stem cells have now cured. The bill under consideration proposes that physicians can use their own stem cells to treat conditions under their discretion if those stem cells are properly expanded, managed, handled and provided to clinicians for them at or above the proposed standards, which is the best news patients with incurable diseases for which no existing cure is available by current medicine have had in a long time.

When the bill is passed, high standards will be established and the better methods will immediately be made obvious to both government and patients. Through this the stem cell community expects a leap in industrial growth, and a leap in the ethical adherence of physicians to do no harm to patients and to provide remedies where possible for the aid of their patients.

The Korean medical community also expects not only to see an influx of domestic patients but also many patients from other nations that lack standards for the growth of patients' own stem cells. South Korea, many economists predict, could become the Mecca for stem cell therapeutics.

Read more:
South Korean lawmakers one step from rigorous new system for stem cell Advancement: scientists, physicians and ...

Recommendation and review posted by Fredricko

Large differences in lifetime physician earnings

Posted: September 18, 2012 at 10:11 pm

SACRAMENTO A national study has found that earnings over the course of the careers of primary-care physicians averaged as much as $2.8 million less than the earnings of their specialist colleagues, potentially making primary care a less attractive choice for medical school graduates and exacerbating the already significant shortage of medical generalists.

The results, published online in the journal Medical Care, lead the study's authors to recommend reducing disparities in physician pay to ensure adequate access to primary care, which has been shown to improve health and reduce health-care costs.

"The need for primary-care providers is greater than ever before and expected to grow as millions more Americans become insured under the Affordable Care Act," said J. Paul Leigh, lead author of the study, professor of public health sciences and researcher with the UC Davis Center for Healthcare Policy and Research. "Without a better payment structure, there will be extraordinary demands on an already scarce resource."

According to projections by the Association of American Medical Colleges, the nation is likely to face a shortage of more than 65,000 primary-care physicians by 2025.

For the nationwide study, a follow-up to 2010 research by Leigh and his colleagues on differences in annual wages by specialty, the investigators compared lifetime earnings to demonstrate how annual wage differences accumulate over physicians' careers. The earnings data came from the 2004-05 Community Tracking Study, a periodic evaluation of physician demographic, geographic and market trends.

To ensure valid comparisons, the data were adjusted to account for factors that affect earnings, including age, sex, race, board certification, graduation from a foreign medical school, rural residence, employment by an academic medical school and residency program length.

Incomes were then evaluated for more than 6,000 doctors practicing in 41 specialties. When merged into four broad career categories, lifetime earnings in surgery, internal medicine and pediatric subspecialties, and all other medical specialties averaged from $761,402 to $1,587,722 higher than in primary care:

The earnings differences were more dramatic when compared as 41 separate specialties. Medical oncologists, for instance, earn up to $7,127,543 during a 35-year career, while family medicine practitioners earn as low as $2,838,637.

Leigh surmised that one reason for the earnings differences is the tendency for Medicare administrators to utilize recommendations from an American Medical Association committee on physician pay that price specialist procedures far higher than primary-care office visits. Private insurance companies, in turn, tend to adopt Medicare pay rates.

The authors noted that efforts are under way to resolve physician pay differences. For example, the Affordable Care Act requires states to pay primary-care physicians no less than 100 percent of Medicare payment rates for primary-care services provided to Medicaid patients. The study's senior author, Richard Kravitz, a UC Davis professor of internal medicine, also serves on an independent commission to assess physician pay.

Go here to see the original:
Large differences in lifetime physician earnings

Recommendation and review posted by G. Smith

Med school admits largest class ever

Posted: September 18, 2012 at 10:11 pm

The Alpert Medical School welcomed its largest class ever this year totalling 120 students following the opening of the schools downtown facility last fall. With the building constructed in downtown Providences Knowledge District able to accommodate more students, the school matriculated 11 additional students in this years class, up from 109 in the class of 2015. The school has expanded from 310 students in 2001 to 421 students this year, according to Ed Wing, dean of medicine and biological sciences.

The admittance of the Med Schools largest-ever class was made possible by the new facility, Wing said. Admitting classes of 120 will expand the school to 480 students in the next few years, he said.

Its a terrific building, Wing said, adding that the schools old space in the BioMedical Center did not allow for expansion. Everything in the (new) building has allowed us to provide better education.

The Med School also witnessed a surge in applications for spots in the class of 2016, with a roughly 20 percent increase from 2,825 applicants in 2011 to 3,344 applications in 2012, according to Philip Gruppuso, associate dean of medical education and professor of pediatrics.

There is in general a physician shortage in the United States, Gruppuso said. He noted that the Association of American Medical Colleges has called for a substantial increase in the countrys supply of doctors and that the University is hoping to aid this goal. Gruppuso said the Med Schools expansion was part of a long-term process that occurred after administrators received permission from the Liaison Committee on Medical Education, the national accrediting organization for medical degree programs.

Wing said administrators have nothing definite planned to expand the student body any further than 480 students.

The Med School hired more staff to accommodate the larger building, but they did not need to hire more faculty members, Wing said, adding that the school boasts a total of 2,000 faculty members, including 600 full-time clinical faculty. The Med School revamped its curriculum but did not add additional classes or expand the size of courses.

Gruppuso said the University is still considered a small medical school according to national rankings of medical degree programs by size.

We had space and resources and faculty to be able to meet the needs of this number of students, he said. We were very confident this (expansion) was not going to result in any kind of erosion of the quality of the medical program.

As part of its expansion, the Med School introduced a new academy model of advising and training last year, with each class divided into three academies of around 40 students in order to facilitate greater advising services and a better sense of community. Each academy space provides locker and study space, designated advisers and other training services to students to help break down the student body into smaller sections.

Excerpt from:
Med school admits largest class ever

Recommendation and review posted by G. Smith

Med School admits largest class yet

Posted: September 18, 2012 at 10:11 pm

The Alpert Medical School welcomed its largest class ever this year totalling 120 students following the opening of the schools downtown facility last fall. With the building constructed in downtown Providences Knowledge District able to accommodate more students, the school matriculated 11 additional students in this years class, up from 109 in the class of 2015. The school has expanded from 310 students in 2001 to 421 students this year, according to Ed Wing, dean of medicine and biological sciences.

The admittance of the Med Schools largest-ever class was made possible by the new facility, Wing said. Admitting classes of 120 will expand the school to 480 students in the next few years, he said.

Its a terrific building, Wing said, adding that the schools old space in the BioMedical Center did not allow for expansion. Everything in the (new) building has allowed us to provide better education.

The Med School also witnessed a surge in applications for spots in the class of 2016, with a roughly 20 percent increase from 2,825 applicants in 2011 to 3,344 applications in 2012, according to Philip Gruppuso, associate dean of medical education and professor of pediatrics.

There is in general a physician shortage in the United States, Gruppuso said. He noted that the Association of American Medical Colleges has called for a substantial increase in the countrys supply of doctors and that the University is hoping to aid this goal. Gruppuso said the Med Schools expansion was part of a long-term process that occurred after administrators received permission from the Liaison Committee on Medical Education, the national accrediting organization for medical degree programs.

Wing said administrators have nothing definite planned to expand the student body any further than 480 students.

The Med School hired more staff to accommodate the larger building, but they did not need to hire more faculty members, Wing said, adding that the school boasts a total of 2,000 faculty members, including 600 full-time clinical faculty. The Med School revamped its curriculum but did not add additional classes or expand the size of courses.

Gruppuso said the University is still considered a small medical school according to national rankings of medical degree programs by size.

We had space and resources and faculty to be able to meet the needs of this number of students, he said. We were very confident this (expansion) was not going to result in any kind of erosion of the quality of the medical program.

As part of its expansion, the Med School introduced a new academy model of advising and training last year, with each class divided into three academies of around 40 students in order to facilitate greater advising services and a better sense of community. Each academy space provides locker and study space, designated advisers and other training services to students to help break down the student body into smaller sections.

See original here:
Med School admits largest class yet

Recommendation and review posted by G. Smith

New gene offers hope for preventive medicine against fractures

Posted: September 18, 2012 at 10:10 pm

Public release date: 18-Sep-2012 [ | E-mail | Share ]

Contact: Mattias Lorentzon, University of Gothenburg mattias.lorentzon@medic.gu.se 46-031-342-4929 University of Gothenburg

A big international study has identified a special gene that regulates bone density and bone strength. The gene can be used as a risk marker for fractures and opens up opportunities for preventive medicine against fractures. The study, led by the Sahlgrenska Academy, University of Gothenburg, Sweden, was published in the journal PLoS Genetics.

The international study, which involved more than 50 researchers from Europe, North America and Australia and was led by Associate Professor Mattias Lorentzon and Professor Claes Ohlsson at the Sahlgrenska Academy, University of Gothenburg, is based on extensive genetic analyses of the genetic material of 10,000 patients and experimental studies in mice.

Through the combined studies, researchers have succeeded in identifying a special gene, Wnt16, with a strong link to bone density and so-called cortical bone thickness, which is decisive to bone strength.

The genetic variation studied by the international research network could predict, for example, the risk of a forearm fracture in a large patient group of older women.

"In the experimental study, we could then establish that the gene had a crucial effect on the thickness and density of the femur. In mice without the Wnt16 gene, the strength of the femur was up to 61 per cent lower," according to Mattias Lorentzon at the Institute of Medicine, the Sahlgrenska Academy, University of Gothenburg.

The discovery opens up opportunities to develop new medicines to prevent the most common fractures.

"Low cortical bone mass is a decisive factor in, for example, hip and forearm fractures. Unfortunately, the treatments currently used for brittleness of the bones have very little effect on the cortical bone mass," says Mattias Lorentzon.

"If we can learn to stimulate the signaling routes of the Wnt16 gene, we could strengthen the skeleton in these parts too, thereby preventing the most common and serious fractures. The discovery of Wnt16 and its regulation of cortical bone mass is therefore very important," according to Mattias Lorentzon.

Read more from the original source:
New gene offers hope for preventive medicine against fractures

Recommendation and review posted by G. Smith

Sirona Biochem Hires Ray Matthews & Associates

Posted: September 18, 2012 at 10:10 pm

VANCOUVER, BRITISH COLUMBIA--(Marketwire - Sep 18, 2012) - Sirona Biochem Corp. (TSX VENTURE:SBM)(SRBCF)(ZSB.F), a biotechnology company specializing in carbohydrate chemistry technology, is pleased to announce that it is has engaged Ray Matthews & Associates Inc. (RM&A) to provide corporate development and strategic advisory consulting services.

"Ray Matthews and his team have a proven track record in supporting financing efforts for several biotechnology companies," stated Dr. Howard Verrico, President & CEO of Sirona Biochem. "Ray Matthews and Associates joins Sirona Biochem at an exciting time with the company focused on partnering and commercialization. Our company will benefit from RM&A''s broad range of experience in strategic planning, corporate development, investor relations and operational consultation," Dr. Verrico added.

"In our first fund (Advantage), some of our early success was due to holdings which had novel solutions addressing blockbuster markets.Sirona Biochem has a compound in development which has the potential to achieve substantial shareholder value. I am excited to be able to add value and help attract additional talent and networks to advance this program," commented Ray Matthews.

About Sirona Biochem Corp.

Sirona Biochem is a biotechnology company developing diabetes therapeutics, cancer vaccine antigens, skin depigmenting and anti-aging agents for cosmetic use, and biological ingredients.The company utilizes a proprietary chemistry technique to improve pharmaceutical properties of carbohydrate-based molecules. For more information, visit http://www.sironabiochem.com.

About Ray Matthews & Associates Inc.

Ray Matthews & Associates Inc (RM&A) is a strategic advisory firm focusing on corporate development, M&A, strategic planning and boutique IR services to Canadian and U.S.-based companies at all stages of development.For more information on RM&A Inc, please visit http://www.raymatthews.ca.

Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise.Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem''s forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem''s business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations.Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.

More:
Sirona Biochem Hires Ray Matthews & Associates

Recommendation and review posted by G. Smith


Page 11,411«..1020..11,41011,41111,41211,413..11,42011,430..»